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Enhanced  pacing  modalities  in bradycardia  patients:
Can technology  reduce  costs?
Aperfeic¸oamento  das  modalidades  de  pacing  nos  doentes  com  bradicardia:
poderão  as  tecnologias  reduzir  os  custos?
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Several  studies  have  demonstrated  the  deleterious  impact
of  conventional  right  ventricular  apical  pacing  on  car-
diac  performance,  particularly  regarding  the  induction  of
ventricular  dyssynchrony,  deterioration  of  left  ventricular
function  and  development  of  heart  failure.  There  is  also  a
strong  association  with  increased  incidence  of  atrial  fibril-
lation  (AF)  in  patients  requiring  implantation  of  permanent
pacemakers  for  sinus  node  disease  (SND)  or  atrioventricular
block  (AVB),  with  or  without  prior  paroxysmal  AF.1--4
The  ideal  pacing  mode  in  patients  with  SND  is  still  the
subject  of  debate.  Despite  previous  studies  showing  that
atrial-based  pacing,  compared  with  ventricular  pacing,  may
reduce  the  occurrence  of  AF,  these  patients  may  subse-
quently  develop  advanced  AVB,  requiring  ventricular  pacing.
Also,  although  atrial  antitachycardia  pacing  (ATP)  therapies
have  been  associated  with  long-term  reduction  of  the  atrial
tachyarrhythmias  burden  in  patients  with  pacemakers,  the
real  clinical  benefits  of  algorithms  using  ATP  to  prevent  AF
initiation  are  still  under  discussion.5
The  MINimizE  Right  Ventricular  pacing  to  prevent  Atrial
fibrillation  and  heart  failure  (MINERVA)  multicenter  inter-
national  randomized  trial  examined  whether  a  combinedDOI of original article: https://doi.org/10.1016/j.repc.2018.01.
013
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he  managed  ventricular  pacing  (MVP)  algorithm,  designed
o  give  priority  to  intrinsic  ventricular  activation  and  thereby
inimize  ventricular  pacing,  reduced  mortality,  morbid-
ty,  or  progression  to  permanent  AF  when  compared  with
tandard  dual-chamber  pacing.6 The  main  results  showed
hat  this  combination  of  algorithms  was  associated  with
 statistically  and  clinically  significant  lower  risk  of  a
omposite  endpoint  of  death,  cardiovascular  hospitaliza-
ions,  or  progression  to  permanent  AF  at  two-year  follow-up,
ompared  with  standard  DDDR  pacing  in  patients  with  brady-
ardia  and  paroxysmal  or  persistent  atrial  tachyarrhythmias.
Another  study,  by  Padeletti  et  al.,  analyzed  the  MINERVA
lgorithm  for  the  prevention  of  AF  progression  by  randomly
ssigning  patients  to  DDDR  (n=385),  MVP  (n=398),  or  DDDR
ith  ATP  +  MVP  (n=383).7 The  best  results  were  obtained
sing  the  combined  algorithm  of  ATP  +  MVP.  Permanent  or
ersistent  AF  was  significantly  reduced  in  patients  with  high
TP  efficacy  (hazard  ratio  [HR]  0.32;  95%  confidence  inter-
al  [CI]  0.13-0.78;  p=0.012)  and  in  those  with  high  atrial
acing  (HR  0.98;  95%  CI  0.97-0.99;  p=0.011);  conversely,  a
igher  risk  of  permanent  or  persistent  AF  was  associated
ith  higher  ventricular  pacing  (HR  1.03;  95%  CI  1.02-1.05;
<0.001).
In  this  issue  of  the  Journal,  Sousa  et  al.  present  the
esults  of  a  complementary  study  in  which  they  performed  a
ealthcare  cost  analysis  of  enhanced  pacing  modalities  in  a
sevier Espan˜a, S.L.U. All rights reserved.
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ortuguese  population,  based  on  the  results  of  the  MINERVA
rial.8 Previously,  Boriani  et  al.  also  performed  a  healthcare
ost  analysis  focused  on  MINERVA,  with  data  from  the  USA,
taly,  Spain  and  the  UK.9 They  demonstrated  significant  sav-
ngs  using  this  algorithm  regarding  utilization  of  AF-related
ealth  resources,  resulting  in  significant  cost  reduc-
ions  in  medical  practice  across  these  diverse  healthcare
ystems.
The  present  study  calculated  the  cost  impact  of  the
TP+MVP  algorithm,  using  the  same  methodology  as  in  Bori-
ni  et  al.,9 with  an  analysis  of  the  Portuguese  tariffs  for
F-related  hospitalizations  and  for  emergency  department
nd  unscheduled  outpatient  visits.  According  to  the  authors,
he  cost  saving  associated  with  the  use  of  this  combined
lgorithm  could  be  17  118  euros  per  100  patients  over  a
0-year  period  (the  estimated  lifetime  of  the  device).
These  national  tariffs,  based  on  data  published  by  the
entral  Administration  of  the  Portuguese  National  Health
ystem  (ACSS),  do  not  consider  specific  costs  for  hospital
dmissions  due  to  AF,  or  for  hospitalizations  or  outpatient
r  emergency  care  visits  in  patients  with  implantable  pulse
enerators.10,11 This  may,  of  course,  have  led  to  under-
stimation  of  the  associated  healthcare  costs  in  such  a
omplex  population.  Moreover,  there  are  no  published  data
n  the  proportion  of  patients  undergoing  pacemaker  implan-
ation  presenting  with  previous  atrial  tachyarrhythmias.
ortugal  has  one  of  the  highest  rates  of  pacemaker  implan-
ation  in  Europe  (1000  per  million  population)  (Sanfins,
t  al.  Registo  Nacional  de  Pacing  Cardíaco;  Associac¸ão
ortuguesa  de  Arritmologia,  Pacing  e  Eletrofisiologia;  Arrit-
ias  2018  -  oral  communication).  Considering  the  growing
revalence  of  AF  and  the  aging  of  the  Portuguese  popula-
ion,  a  reduction  in  AF-related  health  resource  utilization
ould  contribute  to  significant  savings  in  the  healthcare  sys-
em.
Interestingly,  compared  to  the  data  from  the  USA,  the
K,  Italy,  and  Spain  used  by  Boriani  et  al.,9 the  average
ariff/costs  per  episode  in  Portugal  were  between  38%  and
2%  lower  for  hospital  admissions,  and  22%  to  76%  lower  for
mergency  department  visits.  Costs  associated  with  outpa-
ient  visits  were  higher  than  in  Italy,  similar  to  those  in  Spain
nd  lower  than  in  the  USA  and  the  UK.  An  update  of  the
osts  of  healthcare  utilization  for  specific  clinical  situations
equiring  hospitalizations  and  emergency  care  visits,  and
osts  of  outpatient  visits  according  to  the  type  of  cardiac
lectronic  device  implanted,  could  potentially  increase  the
ost  savings  calculated  by  Sousa  et  al.  In  fact,  the  MINERVA
acing  algorithm  was  associated  with  reductions  of  42%  and
8%  in  the  event  rates  for  hospitalization  and  emergency
epartment  visits,  respectively,  which  may  also  be  associ-
ted  with  significant  benefits  regarding  healthcare  costs.7
Finally,  this  analysis,  focusing  on  the  cost  savings
btained  by  using  a  combination  of  ATP  +  MVP  in  patients
ith  previous  atrial  arrhythmias  undergoing  dual-chamber
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acemaker  implantation  due  to  SND,  did  not  take  into  con-
ideration  the  pricing  of  the  devices,  and  it  should  therefore
e  borne  in  mind  that  the  potential  benefits  assume  that
rices  for  these  devices  will  remain  similar.
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